Table 3. Patient and clinicopathologic characteristics.
| Patient characteristics | ||||
|---|---|---|---|---|
| Benign group | Malignant group | Total | p value | |
| n | 31 | 91 | 122 | |
| Age (yrs) | 32 (26-43) |
68 (57-76) |
62 (45-74) |
<0.001* |
| BMI | 21.8 (20.4-26.2) |
26.9 (24.2-30.5) |
25.9 (22-29.08) |
0.002* |
| Menopause | 5/31 (16.1%) | 80/91 (87.9%) | 85/122(69.7%) | <0.0011** |
| Pathologic characteristics | ||||
| Tumor type (St. Gallen consensus) | ||||
| Malignant tumors | Luminal A | 20/91 (22%) | ||
| Luminal B | 58/91 (63.7%) | |||
| Her 2 positive | 4/91 (4.40%) | |||
| Triple negative | 9/91 (9.90%) | |||
| Metastasis | ||||
| Malignant tumors | Lymph node negative | 50/91 (54.9%) | ||
| Lymph node positive | 41/91 (45.1%) | |||
| Tumor differentiation | ||||
| Malignant tumors | Well-differentiated tumors (grade I) |
22 (24.2%) | ||
| Moderately differentiated tumors (grade II) | 42 (46.2%) | |||
| Poorly differentiated tumors (grade III) |
27 (29.7%) | |||
| Ki67 (%) | ||||
| Malignant tumors | Low (0-15%) |
10 (11%) | ||
| Moderate (16%-30%) |
28 (30.8%) | |||
| High (31%-100%) |
53 (58.2%) | |||
n = number of patients; BMI = body mass index; *Mann Whitney U test, data are presented as median and interquartile range limits, p<0.05 was considered significant; **Fisher exact test, p<0.05 was considered significant